Trial · NCT00783289
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TEAEs | 3 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 25 mg | TEAEs | 4 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 100 mg | TEAEs | 4 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 200 mg | TEAEs | 4 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Placebo | TESAEs | 0 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 25 mg | TESAEs | 0 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 100 mg | TESAEs | 0 | participants | |
| Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Benralizumab 200 mg | TESAEs | 0 | participants | |
| Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab | Benralizumab 25 mg | 7.00 | Full Range 7.00 to 28.00 | days | |
| Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab | Benralizumab 100 mg | 7.00 | Full Range 1.00 to 7.00 | days | |
| Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab | Benralizumab 200 mg | 7.00 | Full Range 7.00 to 7.00 | days | |
| Maximum Observed Serum Concentration (Cmax) for Benralizumab | Benralizumab 25 mg | 1.152 | Standard Deviation 0.615 | microgram per milliliter (mcg/mL) | |
| Maximum Observed Serum Concentration (Cmax) for Benralizumab | Benralizumab 100 mg | 4.127 | Standard Deviation 1.775 | microgram per milliliter (mcg/mL) | |
| Maximum Observed Serum Concentration (Cmax) for Benralizumab | Benralizumab 200 mg | 15.637 | Standard Deviation 8.062 | microgram per milliliter (mcg/mL) | |
| Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab | Benralizumab 25 mg | 118.335 | Standard Deviation 69.640 | microgram*day per milliliter | |
| Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab | Benralizumab 100 mg | 405.868 | Standard Deviation 205.856 | microgram*day per milliliter | |
| Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab | Benralizumab 200 mg | 1157.013 | Standard Deviation 86.444 | microgram*day per milliliter | |
| Terminal Phase Elimination Half-Life (t1/2) for Benralizumab | Benralizumab 25 mg | 17.163 | Standard Deviation 2.368 | days | |
| Terminal Phase Elimination Half-Life (t1/2) for Benralizumab | Benralizumab 100 mg | 18.610 | Standard Deviation 3.905 | days | |
| Terminal Phase Elimination Half-Life (t1/2) for Benralizumab | Benralizumab 200 mg | 18.315 | Standard Deviation 3.484 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00783289/results